Spotlight

UCL Enterprise Annual Review 2013/2014

Welcome to the third full year of the delivery phase of UCL’s enterprise strategy. As anticipated, our community continues to strive for excellence and that approach and commitment is clearly working. From working with corporations to assisting student entrepreneurs and spinning out research, We hope that you will enjoy reading about all our enterprise activities from across the university in this Annual Review for 2013/2014.

Professor Stephen Caddick
Vice-Provost (Enterprise and London)

Read the UCL Enterprise Annual Review



follow us on twitter


Spirogen sold to AstraZeneca

16 October 2013

AstraZeneca to pay $440m for UK biotech business
Pharmaceutical group makes acquisition in oncology group spun out of university
Read: Guardian

AstraZeneca Buys Spirogen for $440 Million
MedImmune Unit Also Enters Deal with ADC Therapeutics
Read: Wall Street Journal